Dr Reddy's LaboratoriesFRA:RDDA +3.33%91 Dividend Yield % is 0.64% as of Jun. 25, 2026, which is 2% below its 10-year median of 0.65. GuruFocus rates FRA:RDDA with a GF Score™ of 91/100 and a GF Value™ of €13.16 (Fairly Valued). The stock has 5 warning signs investors should review. Among 516 Drug Manufacturers companies, Dr Reddy's Laboratories ranks worse than 79.26% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Dr Reddy's Laboratories is 0.64%.
The historical rank and industry rank for Dr Reddy's Laboratories's Dividend Yield % or its related term are showing as below:
FRA:RDDA'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.38 Med: 0.65 Max: 1.03
Current: 0.64
During the past 13 years, the highest Dividend Yield of Dr Reddy's Laboratories was 1.03%. The lowest was 0.38%. And the median was 0.65%.
FRA:RDDA's Dividend Yield % is ranked worse than 79.26% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.005
vs FRA:RDDA: 0.64
During the past 3 years, the average Dividends Per Share Growth Rate was 10.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 12.30% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 8.90% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Dr Reddy's Laboratories was 171.40% per year. The lowest was -10.60% per year. And the median was 14.50% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Dr Reddy's Laboratories (FRA:RDDA) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Reddy's Laboratories Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Dr Reddy's Laboratories's Dividend Yield % falls into.
Dr Reddy's Laboratories Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Dr Reddy's Laboratories Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.091485
2025-07-25
2025-07-10
2025-08-06
Cash Dividend
annually
USD:EUR 0.857000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories (FRA:RDDA) has a Dividend Yield % of 0.64% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Dr Reddy's Laboratories and its competitors. This is near median its historical median of 0.65. Over the past decade, Dr Reddy's Laboratories' Dividend Yield % has ranged from 0.38 to 1.03. According to the industry distribution chart, Dr Reddy's Laboratories ranks #409 out of 516 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is Dr Reddy's Laboratories' Dividend Yield % too high?
Dr Reddy's Laboratories' current Dividend Yield % of 0.64% is near median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 1.03. The Drug Manufacturers industry median Dividend Yield % is 2.01. Dr Reddy's Laboratories' value of 0.64% is 68.1% below this industry median. Based on the distribution chart, Dr Reddy's Laboratories ranks #409 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dr Reddy's Laboratories has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dr Reddy's Laboratories ranks #409 out of 516 companies for Dividend Yield %. This places Dr Reddy's Laboratories in the lower half of its industry. The industry median Dividend Yield % is 2.01. Dr Reddy's Laboratories' value of 0.64% is 68.1% below this benchmark. Historically, Dr Reddy's Laboratories' own Dividend Yield % has ranged from 0.38 to 1.03 over the past decade. While the company's 10-year median is 0.65 vs. the industry median of 2.01, Dr Reddy's Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.01, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr Reddy's Laboratories's current Dividend Yield % of 0.64% is 68.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Dr Reddy's Laboratories and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Reddy's Laboratories's current Dividend Yield % is 0.64%, which is near median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (FRA:RDDA) is currently considered Fairly Valued. The stock's GF Value™ is €13.16, compared to a current price of €12.40 — trading 5.8% below its estimated fair value. The current Dividend Yield % is 0.64%, which is near median its 10-year median of 0.65 and 68.1% below the Drug Manufacturers industry median of 2.01. Dr Reddy's Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Dr Reddy's Laboratories (FRA:RDDA), the current Dividend Yield % is 0.64% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr Reddy's Laboratories (FRA:RDDA) Overvalued in 2026?
Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued.
The current stock price of €12.40 is trading 5.8% below its estimated GF Value™ of €13.16.
GuruFocus considers Dr Reddy's Laboratories to be Fairly Valued.
Key valuation signals for FRA:RDDA:
Dividend Yield %: 0.64% (near median its 10-year median of 0.65)
GF Value™: €13.16 vs. price of €12.40 (5.8% below fair value)
Industry Position: 68.1% below the Drug Manufacturers median (#409 of 516)
No single metric tells the full story. See the FRA:RDDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
91GF Score
Get the complete analysis for FRA:RDDA
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RDDA has been successfully added to your 
